Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AMLX
SELLAmylyx Pharmaceuticals, Inc. · Healthcare · United States · $2.0B · Avg Vol: $34M/d
COMPANY DESCRIPTION
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing novel treatments for neurodegenerative diseases, most notably Amyotrophic Lateral Sclerosis (ALS). The company's competitive moat is derived from its innovative drug candidates addressing high unmet medical needs and the regulatory approvals achieved for its key product in major markets. It focuses on improving the lives of patients with devastating neurological conditions.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 22.2M | 380.8M | 87.4M | 0 | 98.3% | — | — | 29.4M | -30.5% |
| EPS | -1.59 | -3.39 | 0.73 | -4.43 | -1.53 | — | -1.46 | -1.43 | -1.36 | — |
| Shares | — | 66.5M | 67.7M | 68.6M | 109.9M | +65.2% | 111.2M | — | — | — |
| Debt | — | 6.3M | 4.2M | 2.0M | 6.0M | -1.7% | 5.6M | — | — | — |
| Equity | — | 340.6M | 433.4M | 164.8M | 305.3M | -3.6% | — | — | — | — |
| Op CF | — | -179.9M | 11.9M | -167.6M | -123.3M | — | -120.4M | — | — | — |
| Inv CF | — | -239.0M | 92.1M | 75.7M | 14.0M | — | — | — | — | — |
| Fin CF | — | 431.8M | 3.5M | 0.3M | 257.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AMLX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals, Inc.(you) | $2.0B | 28 | SELL |
| HROW | Harrow, Inc. | $1.5B | 35 | SELL |
| BIOA | BioAge Labs, Inc. | $968M | 31 | SELL |
| ESPR | Esperion Therapeutics, Inc. | $817M | 33 | SELL |
| GLAS | Glass House Brands Inc. | $899M | 35 | HOLD |
| CURA.TO | Curaleaf Holdings, Inc. | $2.5B | 51 | HOLD |
| HIMS | Hims & Hers Health, Inc. | $6.5B | 32 | SELL |
| VREO.CN | Vireo Growth Inc. | $500M | 36 | HOLD |
| XERS | Xeris Biopharma Holdings, Inc. | $1.4B | 58 | HOLD |
| AQST | Aquestive Therapeutics, Inc. | $462M | 18 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%